{
  "id": "6020b2b21cb411341a000086",
  "type": "factoid",
  "question": "Which cancer can be treated with Darolutamide?",
  "ideal_answer": "Darolutamide is used for treatment of nonmetastatic castration-resistant prostate cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32905676",
    "http://www.ncbi.nlm.nih.gov/pubmed/31571146",
    "http://www.ncbi.nlm.nih.gov/pubmed/32282865",
    "http://www.ncbi.nlm.nih.gov/pubmed/31582533",
    "http://www.ncbi.nlm.nih.gov/pubmed/33237495",
    "http://www.ncbi.nlm.nih.gov/pubmed/32073798",
    "http://www.ncbi.nlm.nih.gov/pubmed/28851578",
    "http://www.ncbi.nlm.nih.gov/pubmed/33226524",
    "http://www.ncbi.nlm.nih.gov/pubmed/32456317",
    "http://www.ncbi.nlm.nih.gov/pubmed/32430485",
    "http://www.ncbi.nlm.nih.gov/pubmed/32822968",
    "http://www.ncbi.nlm.nih.gov/pubmed/31972568",
    "http://www.ncbi.nlm.nih.gov/pubmed/32125151",
    "http://www.ncbi.nlm.nih.gov/pubmed/31605368",
    "http://www.ncbi.nlm.nih.gov/pubmed/31571095",
    "http://www.ncbi.nlm.nih.gov/pubmed/30763142",
    "http://www.ncbi.nlm.nih.gov/pubmed/31953000",
    "http://www.ncbi.nlm.nih.gov/pubmed/30824428",
    "http://www.ncbi.nlm.nih.gov/pubmed/32278840",
    "http://www.ncbi.nlm.nih.gov/pubmed/33141615",
    "http://www.ncbi.nlm.nih.gov/pubmed/33135506",
    "http://www.ncbi.nlm.nih.gov/pubmed/32534790",
    "http://www.ncbi.nlm.nih.gov/pubmed/32924096",
    "http://www.ncbi.nlm.nih.gov/pubmed/32605736",
    "http://www.ncbi.nlm.nih.gov/pubmed/32436836",
    "http://www.ncbi.nlm.nih.gov/pubmed/31695432"
  ],
  "snippets": [
    {
      "text": "Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31972568",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer, and addition of EBRT resulted in even further enhanced antitumor efficacy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31582533",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The antiandrogen therapeutics apalutamide and darolutamide entered the clinic in 2018 and 2019, respectively, for the treatment of castration-resistant prostate cancer (CRPC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32125151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This has been further verified by the recent FDA approval of the other two second-generation AR antagonists, apalutamide and darolutamide, for the treatment of prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32456317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend survival times and improve quality of life in patients with advanced prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32430485",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Darolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32534790",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: NSAAs improve survival in high-risk nmCRPC. Apalutamide and enzalutamide may result in improved oncologic outcomes. Darolutamide may result in fewer AEs. Phase IV data are needed to validate these findings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32278840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Darolutamide for treatment of castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32282865",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Darolutamide is a novel, nonsteroidal androgen receptor (AR)-signaling inhibitor. It serves as a second-generation antiandrogen and is currently indicated for the treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32282865",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Darolutamide, a structurally distinct androgen receptor inhibitor approved for the treatment of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), has been shown to increase metastasis-free survival among men with nmCRPC compared with placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33141615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33141615",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31571095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30763142",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Darolutamide, an oral androgen receptor inhibitor, has been approved for treating nonmetastatic castration-resistant prostate cancer (nmCRPC), based on significant improvements in metastasis-free survival (MFS) in the ARAMIS clinical t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33226524",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on positive results in the phase III ARAMIS trial, darolutamide was recently approved in the USA for the treatment of men with non-metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31605368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28851578",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Darolutamide, a structurally distinct androgen receptor inhibitor approved for the treatment of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), has been shown to increase metastasis-free survival among men with nmCRPC compared with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33141615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31695432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Darolutamide For Castration-Resistant Prostate Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31695432",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32073798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32605736",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTRODUCTION: Studies using apalutamide, enzalutamide, or darolutamide have shown improved metastasis free survival (MFS) rates, leaving clinicians with a dilemma of choosing one over the other, for nonmetastatic castration recurrent prostate cancer (nmCRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32605736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31571146",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32924096",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Apalutamide and enzalutamide appear to be more efficacious agents for therapy of nmCRPC, while darolutamide appears to have the most favorable tolerability profile. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32924096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237495",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " In the pivotal multinational, phase 3 ARAMIS trial in men with nmCRPC, relative to placebo plus ongoing androgen deprivation therapy (ADT), darolutamide (+ ADT) significantly prolonged metastasis-free survival (MFS) at the time of the primary analysis and overall survival (OS) at the time of the final OS analysis and was generally well tolerated in extended follow-up. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237495",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30824428",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since 2018, apalutamide, darolutamide, and enzalutamide have been approved for the treatment of men with non-metastatic castration-resistant prostate cancer (M0CRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32822968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apalutamide, enzalutamide, and most recently, darolutamide (novel androgen receptor antagonists) have been approved for nonmetastatic castration-resistant prostate cancer (nmCRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33135506",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Nonmetastatic castration-resistant prostate cancer"
}